• Mirum Pharmaceuticals reported positive topline VISTAS Phase 2b results for volixibat in primary sclerosing cholangitis related cholestatic pruritus.
• The trial showed a robust, clinically meaningful improvement in itch symptoms for PSC patients, who currently have no approved treatment options.
• Following the data, Mirum has a pre NDA meeting scheduled and plans to file for regulatory approval for volixibat.

For investors tracking Mirum Pharmaceuticals, ticker NasdaqGM:MIRM, this update sits alongside a share price of $102.185 and multi year returns, including about 127.0% over the past year and around 7x over the past 5 years. The stock is also up 30.9% year to date, although it is down 4.6% over the past week, which gives a sense of how closely the market is reacting to new clinical and regulatory milestones.

The VISTAS Phase 2b result adds a potential therapy candidate to Mirum's existing pipeline focus in rare liver diseases and sets up a series of key regulatory events around the planned NDA filing. As those milestones approach, attention is likely to focus on how volixibat might fit into care for PSC patients and what successful approval could mean for Mirum's future product mix and risk profile.

Stay updated on the most important news stories for Mirum Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Mirum Pharmaceuticals.

Investor Checklist

Quick Assessment

• ✅ Price vs Analyst Target: At US$102.19, the stock trades about 30% below the US$146.73 consensus target.
• ✅ Simply Wall St Valuation: Shares are flagged as trading 75.6% below the platform's estimated fair value.
• ✅ Recent Momentum: The stock is up 4.3% over the past 30 days, suggesting positive short term sentiment around the VISTAS data.

There is only one way to know the right time to buy, sell or hold Mirum Pharmaceuticals. Head to Simply Wall St's company report for the latest analysis of Mirum Pharmaceuticals's fair value.

Key Considerations

• 📊 Successful VISTAS Phase 2b results position volixibat as a potential first treatment option in PSC related cholestatic pruritus, which could reshape Mirum's future product mix if it progresses through approval.
• 📊 Keep an eye on the pre NDA meeting, the timing and outcome of the planned filing, and how the share price tracks versus the US$146.73 analyst target.
• ⚠️ The company is assessed as having less than one year of cash runway, so funding plans around further development and launch costs matter as much as the positive trial result.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Mirum Pharmaceuticals analysis. Alternatively, you can visit the community page for Mirum Pharmaceuticals to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.